Food Allergy Treatment Market to Reach USD 15.8 Billion by 2034, Growing from USD 4.5 Billion in 2025 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - Food allergy diagnoses among children climbed roughly 50% between 1997 and 2011, according to the Centers for Disease Control and Prevention, a statistic that continues to reverberate through treatment demand today. The global food allergy treatment market is valued at USD 4.5 billion in 2025 and is projected to reach USD 15.8 billion by 2034, expanding at a CAGR of 15.00% during the forecast period, the fastest growth rate among Strategic Revenue Insights Inc.'s recent healthcare coverage. The findings draw on primary interviews with allergists, immunologists, pediatricians, and specialty pharmacy stakeholders, combined with secondary research across Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa, led by lead analyst Anirudh Singh.

Key Takeaways

• The food allergy treatment market is valued at USD 4.5 billion in 2025 and is forecast to reach USD 15.8 billion by 2034, a CAGR of 15.00%.
• Oral Immunotherapy leads the market on effectiveness, while Biologic Therapy is the fastest-growing segment as targeted treatments advance.
• Personalized, allergen-specific treatment approaches are reshaping product development and patient care delivery.
• North America leads the market on high prevalence rates and healthcare infrastructure, while Asia Pacific is the fastest-growing region amid rising awareness and healthcare access.
• Nestle Health Science (Aimmune), DBV Technologies, and Roche (Genentech) are among the leading competitors.

Full report access: https://www.strategicrevenueinsights.com/industry/food-allergy-treatment-market

Rising Diagnosis Rates Are Colliding With a Thin Treatment Pipeline

The market's growth is rooted in a widening gap between how many people are being diagnosed with food allergies and how many treatment options exist to manage them. As awareness and diagnosis rates climb, more patients are seeking medical intervention to control symptoms and prevent severe reactions, and that demand is compounding with government initiatives and healthcare policies aimed at improving allergy management and treatment accessibility.

Personalized medicine is emerging as the market's defining innovation theme. Advances in medical research have enabled treatments tailored to individual allergen sensitivities, a trend that is especially visible in immunotherapy, where companies are developing therapies that desensitize patients to specific allergens rather than relying on one-size-fits-all approaches. Biologic therapies are advancing in parallel, offering targeted options that address the underlying causes of food allergies rather than just managing symptoms.

Delivery innovation is also reshaping the field. Epicutaneous immunotherapy, which delivers allergens through the skin, is providing a non-invasive alternative to traditional treatment, while digital health tools such as telemedicine and mobile health applications are improving patient access to care and adherence to treatment regimens. Together, these shifts are drawing sustained research and development investment as companies compete to bring safer, more effective therapies to market.

Market Segmentation

By Treatment Type: Oral Immunotherapy leads the market due to its proven effectiveness in managing food allergies, with companies investing in research to enhance its efficacy and safety, while Biologic Therapy is the fastest-growing segment as targeted treatments that address the underlying causes of food allergies advance. Epicutaneous Immunotherapy offers a non-invasive, skin-delivered alternative, and Sublingual Immunotherapy, Emergency Epinephrine Devices, and Avoidance & Management Products round out the segment.

By Allergen Target: Peanut and Tree Nuts are the most common allergens targeted by treatment solutions, reflecting where the bulk of therapy development is concentrated, while demand for Multi-Allergen treatments is rising as companies develop therapies that offer comprehensive solutions for patients with complex allergy profiles. Milk and Egg are also significant targets, alongside continued development addressing Shellfish, Wheat, Soy, and Sesame.

By Age Group: Children and Adolescents are the primary target demographics, with companies developing age-appropriate formulations and delivery mechanisms to improve treatment adherence and outcomes as pediatric food allergy prevalence rises. Infants & Toddlers and Adults are also significant segments, with personalized treatment approaches gaining traction across both groups as companies expand their product offerings.

By End Use: Hospitals & Allergy Centers are the primary setting for treatment administration, offering patients access to specialized clinical care and expertise, while Home Administration is gaining traction as a convenient, cost-effective alternative to traditional in-clinic treatment. Specialty Allergy Clinics and Retail & Hospital Pharmacies continue to serve as important channels as personalized treatment approaches expand across settings.

Regional Outlook

North America and Europe currently dominate the market due to high prevalence rates of food allergies and well-established healthcare infrastructure, with North America identified as the single largest regional market. Asia Pacific is emerging as the fastest-growing region, driven by increasing awareness of food allergies and improving healthcare access, prompting companies to expand their presence through local partnerships and distribution networks. Latin America and the Middle East & Africa round out the report's regional coverage, with Latin America also highlighted as an emerging opportunity alongside Asia Pacific as healthcare infrastructure improves.

Competitive Landscape

Nestle Health Science (Aimmune) is known for its innovative, allergen-specific approach to allergy management, offering patients personalized treatment options backed by strategic partnerships with leading research institutions. DBV Technologies is recognized for its pioneering work in epicutaneous immunotherapy, with its flagship Viaskin product delivering allergens through the skin as a non-invasive, convenient treatment option, supported by a global presence and pharmaceutical alliances. Roche (Genentech) is a leader in biologic therapies, with a focus on precision medicine and targeted treatments backed by a robust pipeline and strategic partnerships with healthcare providers and research institutions.

Market Restraints

The stringent regulatory environment poses challenges for product approvals and market entry, as companies must navigate complex safety and efficacy requirements that can be time-consuming and costly. The high cost of allergy treatments, combined with limited reimbursement options in some regions, also restricts patient access and adoption, while the risk of adverse reactions associated with allergy treatments can affect patient confidence and treatment adherence.

Related Reports

https://www.strategicrevenueinsights.com/industry/digital-therapeutics-mental-health-tech-market

https://www.strategicrevenueinsights.com/industry/digital-x-ray-equipment-market

https://www.strategicrevenueinsights.com/industry/ecg-resting-system-market

https://www.strategicrevenueinsights.com/industry/electrosurgery-market

https://www.strategicrevenueinsights.com/industry/ent-devices-market

Frequently Asked Questions

What is the food allergy treatment market size in 2025?

The global food allergy treatment market was valued at USD 4.5 billion in 2025 and is projected to reach USD 15.8 billion by 2034, growing at a CAGR of 15.00%.

What is driving growth in the food allergy treatment market?

Growth is driven by the increasing prevalence and diagnosis of food allergies, government initiatives to improve allergy management, and rising demand for personalized, targeted treatment approaches.

Which region leads the food allergy treatment market?

North America leads the market due to high prevalence rates and advanced healthcare infrastructure, while Asia Pacific is the fastest-growing region amid rising awareness and healthcare access.

Who are the top companies in the food allergy treatment market?

Leading companies include Nestle Health Science (Aimmune), DBV Technologies, and Roche (Genentech).

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases